StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
96
This year
7
Publishing Date
2023 - 09 - 07
2
2023 - 02 - 28
1
2023 - 02 - 15
1
2023 - 02 - 14
1
2023 - 02 - 10
1
2023 - 01 - 19
1
2023 - 01 - 18
1
2023 - 01 - 10
1
2023 - 01 - 05
1
2022 - 11 - 14
1
2022 - 11 - 09
1
2022 - 10 - 31
1
2022 - 10 - 24
1
2022 - 10 - 20
1
2022 - 10 - 17
1
2022 - 10 - 13
2
2022 - 09 - 29
2
2022 - 09 - 22
1
2022 - 09 - 19
1
2022 - 09 - 08
1
2022 - 08 - 19
1
2022 - 08 - 16
1
2022 - 07 - 26
1
2022 - 05 - 17
1
2022 - 05 - 12
1
2022 - 05 - 11
1
2022 - 05 - 02
1
2022 - 04 - 22
1
2022 - 04 - 21
1
2022 - 03 - 03
1
2022 - 02 - 22
1
2022 - 02 - 15
1
2022 - 02 - 10
1
2022 - 01 - 21
1
2022 - 01 - 07
1
2021 - 12 - 28
1
2021 - 11 - 30
1
2021 - 11 - 15
1
2021 - 11 - 10
1
2021 - 10 - 22
1
2021 - 09 - 29
1
2021 - 09 - 27
1
2021 - 09 - 24
1
2021 - 09 - 15
1
2021 - 09 - 13
1
2021 - 07 - 22
1
2021 - 06 - 29
1
2021 - 06 - 28
1
2021 - 06 - 10
1
2021 - 05 - 17
1
2021 - 05 - 14
1
2021 - 05 - 13
1
2021 - 05 - 04
1
2021 - 04 - 30
1
2021 - 04 - 20
2
2021 - 03 - 05
1
2021 - 02 - 17
1
2021 - 02 - 12
1
2021 - 02 - 10
1
2020 - 12 - 15
1
Sector
Communications
1
Health technology
96
Tags
Agonist
2
Alliances
1
Application
1
Association
2
Biopharma
1
Ces
2
China
1
Clinical-trials-phase-ii
1
Clinical-trials-phase-iii
2
Commercial
1
Conference
18
Designation
1
Diabetic
3
Direct
4
Disease
13
Dry eye
3
Earnings
6
Enroll
1
Europe
1
Events
7
Eye
11
Eye disease
4
Fda
1
Financial
6
Financial results
4
Funding
1
Genetown
1
Glaucoma
1
Global
1
Growth
1
Hypertension
1
Immunology
2
Injection
1
International
2
Ipo
1
N/a
60
Offering
4
Patent
3
Pharm-country
11
Pharmaceuticals
3
Phase 2
5
Pl8177
7
Pl9643
6
Positive
5
Pre-clinical
3
Preclinical
2
Presentation
6
Report
10
Research
7
Results
25
Retina
2
Sales
3
Study
10
Treatment
7
Trial
4
Ulcerative colitis
2
Update
7
Vyleesi
13
Week
2
Year
15
Entities
Adverum biotechnologies, inc.
1
Astrazeneca plc
2
Biogen inc.
1
Cogent biosciences, inc.
1
Icon plc
1
Johnson & johnson
1
Medicinova, inc.
1
Nektar therapeutics
1
Orange
1
Palatin technologies, inc.
96
Sanofi
1
Sutro biopharma, inc.
2
Syndax pharmaceuticals, inc.
1
Tc biopharm (holdings) ltd
2
Vaxart, inc.
1
Symbols
AMBO
69
AMPE
92
AMRN
138
AMS
73
ANVS
103
ASM
60
ATNM
94
BRBS
63
BTG
133
CANF
80
CMCL
158
CRMD
80
CTO
64
DXR
92
ELMD
69
EQX
125
GAU
62
GLDG
90
GOLD
56
GOOG
182
GOOGL
182
GPL
69
GSAT
57
GTE
76
IBIO
84
ITRG
64
JNJ
144
KLR
64
LCTX
109
LEU
68
MLSS
81
MOR
180
MPSYF
180
MTNB
61
NAVB
62
NBY
71
NEM
78
NGD
118
NHC
62
NKTR
180
NXE
95
OCX
487
PHGE
70
PINE
58
PLX
65
PTCT
156
PTN
96
REI
69
SIF
118
SILV
59
STXS
62
SVM
108
TGB
94
TMQ
58
TXMD
181
UAVS
62
UUUU
118
VXRT
182
XXII
110
ZOM
64
Exchanges
Amex
96
Nasdaq
6
Nyse
1
Crawled Date
2023 - 09 - 07
2
2023 - 02 - 28
1
2023 - 02 - 15
1
2023 - 02 - 14
1
2023 - 02 - 10
1
2023 - 01 - 19
1
2023 - 01 - 18
1
2023 - 01 - 10
1
2023 - 01 - 05
1
2022 - 11 - 14
1
2022 - 11 - 09
1
2022 - 10 - 31
1
2022 - 10 - 24
1
2022 - 10 - 20
1
2022 - 10 - 17
1
2022 - 10 - 13
2
2022 - 09 - 29
2
2022 - 09 - 22
1
2022 - 09 - 19
1
2022 - 09 - 08
1
2022 - 08 - 19
1
2022 - 08 - 16
1
2022 - 07 - 26
1
2022 - 05 - 17
1
2022 - 05 - 12
1
2022 - 05 - 11
1
2022 - 05 - 02
1
2022 - 04 - 22
1
2022 - 04 - 21
1
2022 - 03 - 03
1
2022 - 02 - 22
1
2022 - 02 - 15
1
2022 - 02 - 10
1
2022 - 01 - 21
1
2022 - 01 - 07
1
2021 - 12 - 28
1
2021 - 11 - 30
1
2021 - 11 - 15
1
2021 - 11 - 10
1
2021 - 10 - 22
1
2021 - 09 - 29
1
2021 - 09 - 27
1
2021 - 09 - 24
1
2021 - 09 - 15
1
2021 - 09 - 13
1
2021 - 07 - 22
1
2021 - 06 - 29
1
2021 - 06 - 28
1
2021 - 06 - 10
1
2021 - 05 - 17
1
2021 - 05 - 14
1
2021 - 05 - 13
1
2021 - 05 - 04
1
2021 - 04 - 30
1
2021 - 04 - 20
2
2021 - 03 - 05
1
2021 - 02 - 17
1
2021 - 02 - 12
1
2021 - 02 - 10
1
2020 - 12 - 15
1
Crawled Time
11:00
1
12:00
33
12:15
2
12:30
8
13:00
19
13:11
2
13:20
1
13:30
1
14:00
3
15:00
2
15:30
2
18:00
4
20:00
7
21:00
6
22:00
4
23:00
1
Source
www.biospace.com
36
www.palatin.com
17
www.prnewswire.com
42
www.sutrobio.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
Ptn
exchanges :
Amex
save search
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Published:
2024-02-28
(Crawled : 12:30)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-56.42%
|
O:
-44.58%
H:
25.45%
C:
11.36%
pl9643
disease
eye
trial
results
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Published:
2024-02-15
(Crawled : 12:30)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-58.21%
|
O:
-2.66%
H:
0.25%
C:
-21.84%
year
update
financial
results
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
Published:
2024-02-09
(Crawled : 12:30)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-56.97%
|
O:
1.24%
H:
4.42%
C:
4.42%
report
year
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Published:
2024-02-05
(Crawled : 12:30)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-54.23%
|
O:
0.53%
H:
15.53%
C:
7.11%
pl9643
disease
eye
trial
Palatin Announces Closing of $10 Million Registered Direct Offering
Published:
2024-02-01
(Crawled : 21:00)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-52.08%
|
O:
8.03%
H:
0.0%
C:
-3.08%
million
direct
offering
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Published:
2024-01-08
(Crawled : 15:30)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-37.09%
|
O:
1.82%
H:
11.43%
C:
10.71%
year
update
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
Published:
2024-01-03
(Crawled : 18:00)
- biospace.com/
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-55.18%
|
O:
0.0%
H:
1.04%
C:
-10.62%
vyleesi
pharmaceuticals
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Published:
2023-12-20
(Crawled : 12:30)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-28.51%
|
O:
-4.96%
H:
17.83%
C:
7.39%
vyleesi
pharmaceuticals
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Published:
2023-11-14
(Crawled : 12:30)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-13.93%
|
O:
-2.99%
H:
2.56%
C:
-1.54%
year
update
financial
results
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
Published:
2023-11-09
(Crawled : 12:30)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-13.5%
|
O:
0.0%
H:
2.5%
C:
-4.0%
report
year
Palatin Announces Closing of $5 Million Registered Direct Offering
Published:
2023-10-24
(Crawled : 21:00)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-16.43%
|
O:
0.0%
H:
4.95%
C:
-3.38%
direct
offering
Palatin Announces $5 Million Registered Direct Offering
Published:
2023-10-23
(Crawled : 13:30)
- biospace.com/
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-27.92%
|
O:
-17.08%
H:
8.86%
C:
4.02%
direct
offering
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
Published:
2023-10-19
(Crawled : 12:00)
- biospace.com/
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
0.0%
|
O:
1.16%
H:
33.71%
C:
21.14%
vyleesi
results
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
Published:
2023-10-18
(Crawled : 20:00)
- biospace.com/
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-1.7%
|
O:
-3.41%
H:
5.79%
C:
1.76%
agonist
positive
preclinical
study
Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
Published:
2023-10-16
(Crawled : 20:00)
- biospace.com/
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
0.0%
|
O:
0.58%
H:
5.75%
C:
0.57%
pl8177
conference
treatment
week
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
Published:
2023-09-22
(Crawled : 20:00)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
Email alert
Add to watchlist
report
year
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
Published:
2023-09-07
(Crawled : 22:00)
- biospace.com/
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-24.13%
|
O:
0.43%
H:
3.49%
C:
-2.18%
pl9643
disease
treatment
eye
study
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Published:
2023-09-07
(Crawled : 20:00)
- prnewswire.com
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-22.77%
|
O:
-0.89%
H:
0.0%
C:
-6.31%
conference
global
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
Published:
2023-08-10
(Crawled : 13:00)
- biospace.com/
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-40.55%
|
O:
-0.34%
H:
2.86%
C:
-5.17%
treatment
program
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
Published:
2023-08-08
(Crawled : 12:00)
- biospace.com/
PTN
|
$1.73
-1.14%
0.0%
61K
|
Health Technology
|
-20.64%
|
O:
14.68%
H:
11.9%
C:
5.6%
vyleesi
pharma
pharmaceuticals
commercial
china
study
← Previous
1
2
3
4
5
Next →
Gainers vs Losers
61%
39%
Top 10 Gainers
CSSE
4
|
$0.4253
179.25%
64.77%
210M
|
Consumer Services
BOF
|
$2.08
77.78%
41.21%
110M
|
ILAG
|
$0.54
12.27%
40.62%
3.7M
|
LICN
|
$0.999
78.39%
40.49%
15M
|
AMST
|
$3.4
70.0%
39.58%
70M
|
Technology Services
MTC
|
$3.6
60.71%
38.04%
9.1M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.458
14.5%
30.92%
91K
|
Health Services
WHLM
|
$6.25
35.87%
28.46%
700K
|
Commercial Services
MULN
|
News
|
$3.77
38.1%
27.78%
13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.